We held a webinar on Tuesday that allowed us to introduce our Biomarker Intelligence Maturity Model and to announce our new partnership with AdisInsight, a member of the Springer Nature family. We can assure you that the two are related. To see for yourself check out...
This week’s Chart of the Week attempts to communicate recent research on pure manual review of literature versus a combination of human and machine curation. These preliminary results measure the extra amount of time it will take to manually curate results that have...
This week we took a look at FDA-cleared and approved IVDs for oncology, and grouped them based on whether they measure proteins or nucleic acids. Protein-based tests have historically been the dominant type used in the clinic, but this is changing rapidly. Based on...
In a follow on to our trial filtering changes we made in February, this week we have added a couple more options to trial filtering: Filtering biomarkers to those used as outcome and safety measures Filtering trials to only those with results Insights view of...
Anyone involved in biomarkers knows how imperative it is to stay informed about biomarker developments. Here at Amplion, we aggregate and annotate cutting edge biomarker information and publish it in BiomarkerBase, so you can stay up to date on the clinical biomarker...
